Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV MEDI ΔM2-2 vaccine
BIOLOGICAL: Placebo vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)